ArticleMolecular neurobiology2026
Resveratrol Ameliorates Brain Functions During Gestation in Mancozeb-Low-Dose-Induced Brain Disorders via Mitigating Inflammation, Lipid Peroxidation, Mitochondrial Dysfunction, DNA Damage, Cell Death, and Histopathological Alterations.
Article in Molecular neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Worldwide, many old and young people suffer from neurodegenerative brain disorders. Continuous exposure to mancozeb (MNZ), a fungicide extensively used worldwide on a wide range of crops, is a serious threat to public health because of inducing neuroinflammation and oxidative stress. Resveratrol (RES) is a natural polyphenol with antioxidant and anti-inflammatory effects. This study evaluated the neuroprotective potential of RES against MNZ low-dose-induced brain damage during gestation and elucidated its underlying mechanisms. Thirty-two pregnant Wistar rats were randomly allocated into four groups (n = 8): control, RES-treated rats (100 mg/kg/day, intraperitoneal injection), MNZ-treated rats (100 mg/kg/day, oral), and RES + MNZ-treated rats (100 mg/kg/day intraperitoneal before 100 mg/kg/day MNZ oral). Treatments were administered daily from gestational day (GD) 1 to GD 20. On GD 20, brain samples were collected for biochemical, DNA integrity, morphometric, histopathological, and immunohistochemical assays. Gestational MNZ exposure induced neuroinflammation, lipid peroxidation, reduced CAT activity, and triggered GFAP accumulation, resulting in astrogliosis in the cerebrum and hippocampus. Furthermore, MNZ disrupted mitochondrial apoptosis regulatory proteins, increased DNA damage in maternal and fetal brain cells, induced cerebral and hippocampal neurodegeneration, and reduced cortical thickness while increasing the hippocampal stratum lucidum thickness. Remarkably, pretreatment with RES protected the maternal and fetal brains, preserving cerebral and hippocampal-dependent brain functions through suppressing lipid peroxidation, inflammation, mitochondrial-mediated apoptosis, DNA damage, and histopathological changes. In conclusion, RES demonstrates a potent prophylactic neuroprotective efficacy during gestation against MNZ-induced neurotoxicity, suggesting its potential value as a preventive dietary agent against environmental toxin-mediated brain disorders.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.